(E)-4-Methoxycinnamaldehyde is an oviposition deterrent for Delia antiqua research
**Background**
The onion fly, Delia antiqua, is a significant agricultural pest that causes substantial damage to crops by laying eggs on host plants, leading to larval infestation of the root systems. Managing the population of these pests often requires understanding their oviposition behavior to develop effective deterrents that can protect crops without relying solely on broad-spectrum insecticides. Natural compounds derived from plants, particularly those from the Zingiberaceae family, have been investigated for their ability to act as non-specific deterrents to discourage insects from laying eggs. In this context, we will introduce a potent oviposition deterrent – (E)-4-Methoxycinnamaldehyde.
**Definition**
(E)-4-Methoxycinnamaldehyde is a plant-derived aldehyde with the molecular formula C10H10O2 and a molecular weight of 162.19. It serves as a chemical deterrent that inhibits the oviposition behavior of Delia antiqua.
**Biological Activity**
According to the (E)-4-Methoxycinnamaldehyde description, this compound is naturally sourced from the plant Etlingera pavieana (Pierre ex Gagnep.) R.M.Sm. In studies focusing on (E)-4-Methoxycinnamaldehyde biological activity, it was demonstrated that the compound acts as an effective oviposition deterrent against Delia antiqua. When formulated in Polyethylene glycol, (E)-4-Methoxycinnamaldehyde exhibited a BR 90 (the concentration eliciting 90% deterrency) of 0.38%. These findings indicate that the compound can significantly modulate the reproductive behavior of the onion fly, making it a valuable tool for studying insect-plant interactions and developing sustainable pest management strategies. In conclusion, (E)-4-Methoxycinnamaldehyde is a potent oviposition deterrent used to study the behavioral responses of Delia antiqua.
Keywords
(E)-4-Methoxycinnamaldehyde, 24680-50-0, Insecticide, onion fly, Delia antiqua, ovipositional deterrent, polyethylene glycol, egg-laying behavior, Inhibitor, inhibitor, inhibit
References
**Background**
Thiamine, also known as Vitamin B1, is an essential micronutrient that serves as a critical cofactor for numerous central metabolic enzymes. Beyond its role in energy metabolism, thiamine has gained significant attention in biomedical research due to its ability to modulate inflammatory pathways and protect neurological functions. Specifically, it has been shown to activate the Nrf-2/HO-1 antioxidant system while inhibiting pro-inflammatory mediators such as TLR4 and NF-κB. These properties make it a valuable tool in studying diabetic complications, neurological diseases, colitis, and various forms of cancer. In this context, we will introduce a versatile metabolic cofactor and anti-inflammatory agent – Thiamine.
**Definition**
Thiamine hydrochloride is an endogenous metabolite and essential micronutrient that targets TLR4 to exert neuroprotective and anti-inflammatory effects.
**In Vitro and In Vivo Studies**
The Thiamine biological activity has been extensively documented across various experimental models. In terms of Thiamine in vitro studies, treatment with thiamine hydrochloride (0.125-2 μg/mL for 24 h) increases cellular PDH activities and enhances the basal, maximum, and ATP production oxygen consumption rate in MCF7 breast cancer cells. Furthermore, high doses of thiamine (10-100 mM for 5 days) reduce proliferation in the SK-N-BE and Panc-1 cancer cell lines, demonstrating its potential in Thiamine Cancer research. Additionally, thiamine (200 μM) protects human infragenicular arterial smooth muscle cells against glucose- and insulin-mediated proliferation.
Regarding Thiamine in vivo applications, thiamine hydrochloride (300 µg/kg, administered on alternate days for 14 days) ameliorates scopolamine-induced memory dysfunction in adult BALB/C albino mice by reactivating the Nrf-2/HO-1 system and inhibiting the NF-κB/TNF-α pathway. In models of inflammation, thiamine (150-200 mg/kg, i.p. for 21 days) exhibits anti-inflammatory and antihyperalgesic effects in adjuvant-induced arthritis Wistar rats. Moreover, thiamine (20 mg/kg/d, i.p. for 5 days) attenuates macroscopic colon parameters and reduces the total colitis index in rats with colitis. In conclusion, Thiamine is a potent micronutrient with significant neuroprotective, anti-inflammatory, and antiproliferative properties.
Keywords
Thiamine, 67-03-8, Thiamine chloride, Vitamin B1, Vitamin B 1, Vitamin B-1, Endogenous Metabolite, Keap1-Nrf2, Toll-like Receptor (TLR), NF-κB, Nuclear factor-κB, Nuclear factor-kappaB, Neuroprotective, Anti-inflammatory, Neurological diseases, Cancers, and Colitis., Inhibitor, inhibitor, inhibit
References
[1] Moulin M, et al. Analysis of Chlamydomonas thiamin metabolism in vivo reveals riboswitch plasticity. Proc Natl Acad Sci U S A. 2013 Sep 3;110(36):14622-7.
[2] Liu X, et al. The Effects of Thiamine on Breast Cancer Cells. Molecules. 2018 Jun 16;23(6):1464.
[3] Hanberry BS, Berger R, Zastre JA. High-dose vitamin B1 reduces proliferation in cancer cell lines analogous to dichloroacetate. Cancer Chemother Pharmacol. 2014 Mar;73(3):585-94.
[4] Avena R, et al. Thiamine (Vitamin B1) protects against glucose- and insulin-mediated proliferation of human infragenicular arterial smooth muscle cells. Ann Vasc Surg. 2000 Jan;14(1):37-43.
[5] Nasir A, et al. Vitamin B1 via Nrf-2/TLR4 signaling pathway ameliorates scopolamine-induced memory dysfunction in adult mice. Arabian Journal of Chemistry, 2024, 17(1): 105350.
[6] Zaringhalam J, et al. Long-Term Treatment by Vitamin B1 and Reduction of Serum Proinflammatory Cytokines, Hyperalgesia, and Paw Edema in Adjuvant-Induced Arthritis. Basic Clin Neurosci. 2016 Oct;7(4):331-340.
[7] Dalayeli N, et al. Investigating the Impact of Selected B Vitamins (B1, B2, B6, and B12) on Acute Colitis Induced Experimentally in Rats. Int J Prev Med. 2024 Nov 28;15:61.
**Background**
Hypertension is a chronic medical condition characterized by persistently elevated blood pressure in the arteries, which significantly increases the risk of cardiovascular diseases, stroke, and renal failure. Managing blood pressure often involves targeting the sympathetic nervous system to reduce peripheral vascular resistance and cardiac output. Among the various therapeutic strategies, centrally acting agents that modulate adrenergic receptors in the brain provide a potent means of lowering blood pressure. The $\alpha_2$-adrenergic receptor, in particular, plays a critical role in regulating the release of norepinephrine and modulating sympathetic outflow. In this context, we will introduce a potent antihypertensive agent – Methyldopa.
**Definition**
Methyldopa (L-(-)-$\alpha$-Methyldopa hydrate) is an $\alpha$-adrenergic agonist that selectively targets $\alpha_2$-adrenergic receptors. According to the Methyldopa technical information, it serves as a proagent that is metabolized into $\alpha$-methylepinephrine within the central nervous system to exert its pharmacological effects.
**In Vivo Studies**
The Methyldopa biological activity has been explored in various physiological models to understand its systemic impact. In vivo studies utilizing 60-day-old male rats demonstrated that Methyldopa (200 mg/kg; i.p.) can effectively modulate metabolic responses. Specifically, the administration of this compound decreased the hyperglycemic response during the first 2 hours following treatment with Dieldrin. Detailed results indicated that Methyldopa in vivo administration reduced the plasma concentration of glucose in Dieldrin-exposed rats by 24% within the 30 minutes following its delivery. These findings suggest that beyond its primary role in blood pressure regulation, the compound may influence glucose homeostasis in specific toxicological models. In conclusion, Methyldopa is a selective $\alpha_2$-adrenergic agonist with potent antihypertensive properties and metabolic regulatory effects.
Keywords
Methyldopa, 41372-08-1, L-(-)-α-Methyldopa, MK-351, MK351, MK 351, Adrenergic Receptor, Endogenous Metabolite, Beta Receptor, antihyoertensive, prodrug, metabolized, hyperglycemic, response, Inhibitor, inhibitor, inhibit
References
[1] Sweet CS. New centrally acting antihypertensive drugs related to methyldopa and clonidine. Hypertension. 1984;6(5 Pt 2):II51-II56.
[2] Fox GR, et al. The effects of phenobarbital, atropine, L-alpha-methyldopa, and DL-propranolol on dieldrin-induced hyperglycemia in the adult rat. Toxicol Appl Pharmacol. 1985;78(3):342-350.
**Background**
Cyclooxygenase-2 (COX-2) is an enzyme that plays a pivotal role in the synthesis of prostaglandins, which are key mediators of inflammation, pain, and fever. Unlike COX-1, which is constitutively expressed in most tissues to maintain homeostatic functions, COX-2 is typically induced during inflammatory responses. Overexpression of COX-2 has been linked to various pathological conditions, including rheumatoid arthritis, osteoarthritis, and certain types of malignancy. Consequently, the development of selective COX-2 inhibitors has become a primary strategy to reduce inflammation and alleviate pain while minimizing the gastrointestinal side effects associated with non-selective NSAIDs. Beyond inflammation, COX-2 inhibition is also being explored for its potential to suppress tumor growth and carcinogenesis. In this context, we will introduce a selective and orally active COX-2 inhibitor – Etoricoxib.
**Definition**
Etoricoxib (MK-0663) is a non-steroidal anti-inflammatory agent that acts as a selective COX-2 inhibitor, exhibiting IC50 values of 1.1 μM for COX-2 and 116 μM for COX-1 in human whole blood.
**In Vitro and In Vivo Studies**
The Etoricoxib description highlights its potency as a selective inhibitor. In terms of Etoricoxib in vitro activity, the compound demonstrates an IC50 of 5 μM against purified human COX-2 and 1.1 μM in human whole blood. In CHO cells stably expressing human COX-2, Etoricoxib inhibits PGE2 production with an IC50 of 79 nM (0.081 μM). Furthermore, it shows an IC50 of 4.1 μM against purified human COX-2 with detergent and 12.1 μM against PGE2 production by U937 microsomes. Conversely, it exhibits minimal activity against COX-1, with a Ki of 167 μM.
Regarding Etoricoxib in vivo efficacy, administration (0.1-30 mg/kg, p.o.) in rats results in a dose-dependent inhibition of endotoxin-induced pyresis, carrageenan-induced paw edema, and carrageenan-induced paw hyperalgesia, with doses ≥10 mg/kg completely reversing the hyperalgesia response. In models of Etoricoxib Cancer research, doses of 0.64 mg/kg (p.o.) reduce hyperplasia, dysplasia, and multiple plaque lesions induced by 1,2-dimethylhydrazine dihydrochloride (DMH) in rats. Additionally, Etoricoxib (100 mg/kg) significantly inhibits the decrease of NO in rats, while doses of 50 and 100 mg/kg increase malondialdehyde (MDA) and myeloperoxidase (MPO) levels and decrease total glutathione (tGSH) and glutathione reductase (GSHRd) levels. Notably, Etoricoxib can cross the blood-brain barrier rapidly. In conclusion, Etoricoxib is a potent, selective COX-2 inhibitor with significant anti-inflammatory and anti-proliferative properties.
Keywords
Etoricoxib, 202409-33-4, MK-0663, L-791456, MK0663, MK 0663, L791456, L 791456, COX, Cyclooxygenase, Inhibitor, inhibitor, inhibit
References
[1] Riendeau D, et al.Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther. 2001 Feb;296(2):558-66.
[2] Kunak CS, et al. The Effect of Etoricoxib on Hepatic Ischemia-Reperfusion Injury in Rats. Oxid Med Cell Longev. 2015;2015:598162.
[3] Tanwar L, et al. Anti-proliferative and apoptotic effects of etoricoxib, a selective COX-2 inhibitor, on 1,2-dimethylhydrazine dihydrochloride-induced colon carcinogenesis. Asian Pac J Cancer Prev. 2010;11(5):1329-33.
[4] Piirainen A, et al. The Cerebrospinal Fluid Distribution of Postoperatively Administred Dexketoprofen and Etoricoxib and Their Effect on Pain and Inflammatory Markers in Patients Undergoing Hip Arthroplasty. Clin Drug Investig. 2016 Jul;36(7):545-55.
**Background**
Staphylococcal infections and pathogenic protozoa pose significant challenges to human and animal health due to their ability to evade the immune system and develop resistance. Effective treatment requires agents that can disrupt the fundamental structural integrity of the pathogen. Beyond its traditional use as an antimicrobial, recent research has highlighted the role of protein disulfide isomerase (PDI) in various pathological processes, including tumor angiogenesis and the progression of hepatocellular carcinoma (HCC). Inhibiting PDI can induce endoplasmic reticulum (ER) stress and suppress the formation of new blood vessels, making it a promising target for oncology. In this context, we will introduce a versatile polypeptide antibiotic and PDI inhibitor – Bacitracin.
**Definition**
Bacitracin is a polypeptide antibiotic derived from the Tracey I strain of Bacillus subtilis that targets cell wall biosynthesis and acts as a protein disulfide isomerase (PDI) inhibitor.
**In Vitro and In Vivo Studies**
According to the Bacitracin description, this compound inhibits macromolecular synthesis and cell wall permeability by binding to undecaprenyl pyrophosphate. In terms of Bacitracin in vitro activity, the compound (64 μg/mL, 24 h) demonstrated potent antibacterial activity against S. aureus BA01611 when used in combination with Colistin. Furthermore, treatment with Bacitracin (64 μg/mL, 1 or 2 h) was observed to damage the cell surface, resulting in the formation of grape-like cell clusters with faint and unclear cell boundaries.
Regarding Bacitracin in vivo applications, the compound has shown significant potential in Bacitracin Cancer research. In an HCC model using implanted MH134 cells, Bacitracin was administered via intramuscular injection daily for 12 consecutive days at dosages of 0, 10, 50, and 100 mg/kg. The results indicated a dose-dependent decrease in tumor volumes and a reduction in the percentage of PDI-stained vascular densities. These findings suggest that Bacitracin exerts anti-tumor efficacy by augmenting ER stress and inhibiting angiogenesis through PDI inhibition. In conclusion, Bacitracin is a potent polypeptide antibiotic and PDI inhibitor suitable for research in infectious diseases and hepatocellular carcinoma.
Keywords
Bacitracin, 1405-87-4, Bacterial, Antibiotic, PDI, Protein Disulfide Isomerases, Staphylococcal, infection, pathogenic protozoa, HCC, Inhibitor, inhibitor, inhibit
References
[1] Si W, et al. Colistin Induces S. aureus Susceptibility to Bacitracin. Front Microbiol. 2018 Nov 20;9:2805.
[2] Mohamed Faisal, et al. Bacitracin Inhibits the Oyster Pathogen Perkinsus marinus in Vitro and in Vivo. Journal of Aquatic Animal Health. Volume 11, 1999 – Issue 2.
[3] Yu SJ, et al. Enhancement of hexokinase II inhibitor-induced apoptosis in hepatocellular carcinoma cells via augmenting ER stress and anti-angiogenesis by protein disulfide isomerase inhibition. J Bioenerg Biomembr. 2012 Feb;44(1):101-15.
**Background**
Ultraviolet (UV) radiation is a primary environmental stressor that can lead to DNA damage, oxidative stress, and skin aging. To mitigate these effects, organic UV filters are widely utilized in cosmetics to absorb UVB and shorter UVA wavelengths. However, beyond their protective role, certain filters may exhibit unintended biological activities that impact metabolic pathways and cellular health. Peroxisome proliferator-activated receptor gamma (PPARγ) is a nuclear receptor critical for regulating lipid metabolism and adipogenesis, and its dysregulation is linked to metabolic disorders. Understanding the interaction between common chemical filters and these regulatory pathways is essential for assessing their long-term safety and endocrine-disrupting potential. In this context, we will introduce an organic UV filter with complex biological activity – Octocrylene.
**Definition**
Octocrylene is an organic ultraviolet filter that acts as a partial agonist of PPARγ, with a binding affinity (Ki) of 37.8 μM.
**In Vitro and In Vivo Studies**
According to the Octocrylene description, this compound serves as a UV filter but also exhibits significant cytotoxic and genotoxic properties. Octocrylene in vitro studies have demonstrated that treatment with concentrations ranging from 260 to 6500 μM for 24 hours reduces the survival of human skin fibroblasts in a dose-dependent manner, with an IC50 of 1390.95 μM, while simultaneously increasing intracellular oxidative stress and DNA damage. In the zebrafish liver cell line (ZFL), Octocrylene acts as an activator of the ER pathway; concentrations of 25.8 μM (24 h) and 5.5 μM (96 h) increased the expression of genes including CYP1A, CYP3A65, ERα, ERβ1, GPER, VTG1, CYP19A, and DMRT1, while downregulating AhRRB, AIP, ARNTL1A, and 11βHSD. Furthermore, Octocrylene (30 μM) promotes adiponectin production during adipogenesis in hBM-MSCs with an EC50 of 29.6 μM.
Regarding Octocrylene In Vivo activity, zebrafish larvae exposed to 251.8 μM of the compound for 96 hours showed increased expression of CYPs, ER pathway-related genes, and sex differentiation genes, mirroring the results observed in the ZFL cell line. These findings suggest that the compound may interfere with antioxidant pathways, including peroxisomes and glutathione transferase, and mediate the biosynthesis of estrogens such as estriol. For researchers seeking detailed Octocrylene technical information, these results highlight its potential as an obesogen and endocrine disruptor. In conclusion, Octocrylene is an organic UV filter that functions as a PPARγ partial agonist and exhibits cytotoxic, genotoxic, and endocrine-modulating effects.
Keywords
Octocrylene, 6197-30-4, Biochemical Assay Reagents, PPAR, Estrogen Receptor/ERR, Cytochrome P450, Peroxisome proliferator-activated receptors, CYPs, Inhibitor, inhibitor, inhibit
References
[1] E Berardesca, et al. Review of the safety of octocrylene used as an ultraviolet filter in cosmetics. J Eur Acad Dermatol Venereol. 2019 Nov;33 Suppl 7:25-33.
[2] Vatan Ö, et al. Evaluation of cytotoxic and genotoxic potential of avobenzone and octocrylene on human skin fibroblast cells[J]. All Life, 2023, 16(1): 2270171.
[3] Meng Q, et al. Toxic effects of octocrylene on zebrafish larvae and liver cell line (ZFL)[J]. Aquatic Toxicology, 2021, 236: 105843.
[4] Ko H, et al. Sunscreen filter octocrylene is a potential obesogen by acting as a PPARγ partial agonist[J]. Toxicology letters, 2022, 355: 141-149.
[5] de Groot A C, et al. Contact and photocontact allergy to octocrylene: a review[J]. Contact dermatitis, 2014, 70(4): 193-204.
**Background**
Hypertension, commonly known as high blood pressure, is a chronic medical condition where the force of the blood against the artery walls is high enough that it may eventually cause health problems, such as heart disease and stroke. The regulation of blood pressure is complex, involving the sympathetic nervous system and the renin-angiotensin-aldosterone system. Specifically, the activation of alpha-2 adrenergic receptors in the brainstem inhibits the outflow of sympathetic nerves to the heart and blood vessels, thereby reducing peripheral vascular resistance and lowering blood pressure. Consequently, targeting these receptors has become a primary strategy in the development of antihypertensive therapies. In this context, we will introduce an alpha-2 selective adrenergic agonist – Guanabenz.
**Definition**
Guanabenz (Acetate) is an alpha-2 selective adrenergic agonist used as an antihypertensive agent. According to the Guanabenz description, this compound acts centrally to reduce sympathetic outflow, making it a valuable tool for studying cardiovascular regulation.
**In Vitro and In Vivo Studies**
The chemical properties of the compound are defined by the Guanabenz Formula $\text{C}_{10}\text{H}_{12}\text{Cl}_2\text{N}_4\text{O}_2$ and a molecular weight of 291.13. Regarding Guanabenz in vitro activity, it functions as a potent agonist of the alpha-2 type adrenergic receptor. Research focusing on Guanabenz biological activity has demonstrated its efficacy in treating high blood pressure by mimicking the effects of norepinephrine at presynaptic alpha-2 receptors. Comparative studies have analyzed the antihypertensive effects of guanabenz in relation to other agonists like clonidine to determine their relative potency and duration of action. Furthermore, investigations into the mechanism of the central antihypertensive effect have highlighted how guanabenz modulates sympathetic activity to achieve blood pressure reduction. In conclusion, Guanabenz is a selective alpha-2 adrenergic agonist that serves as an effective antihypertensive agent for biomedical research.
Keywords
Guanabenz, 23256-50-0, BR-750, Wy8678, BR750, BR 750, Wy 8678, Wy-8678, Adrenergic Receptor, Beta Receptor, Inhibitor, inhibitor, inhibit
References
[1] Walker, B.R., L.E. Hare, and M.W. Deitch, Comparative antihypertensive effects of guanabenz and clonidine. J Int Med Res, 1982. 10(1): p. 6-14.
[2] Bonham, A.C., et al., Studies on the mechanism of the central antihypertensive effect of guanabenz and clonidine. J Hypertens Suppl, 1984. 2(3): p. S543-6.
**Background**
The Wnt signaling pathway plays a critical role in maintaining cellular homeostasis, embryonic development, and tissue regeneration. Among the receptors involved, Frizzled 4 (FZD4) is a key transmembrane protein that mediates Wnt signaling, which is often dysregulated in various pathological conditions, including neurodegenerative diseases. Aberrant activation of the WNT/β-catenin cascade can contribute to inflammation and oxidative stress, particularly in the brain. Consequently, targeting the allosteric sites of Frizzled receptors provides a sophisticated approach to modulate these pathways without completely blocking ligand binding. In this context, we will introduce a negative allosteric modulator (NAM) of FZD4 – FzM1.
**Definition**
FzM1 is a negative allosteric modulator of the Frizzled receptor FZD4 that reduces WNT5A-dependent WNT responsive element (WRE) activity with a log EC 50inh of -6.2.
**In Vitro and In Vivo Studies**
According to the FzM1 description, this compound binds to an allosteric site located in intracellular loop 3 (ICL3) of FZD4, altering the receptor’s conformation to inhibit the WNT/β-catenin cascade. In terms of FzM1 in vitro activity, studies using HEK293 cells co-transfected with FZD4 and a WNT reporter construct demonstrated that FzM1 acts as a negative allosteric regulator of FZD4 signaling initiated by WNT5A, thereby reducing WNT5A-dependent WRE activity without increasing the activity of the WNT reporter construct. Furthermore, in CaCo-2 cells, treatment with FzM1 (15 μM; 24 h, 48 h) resulted in decreased cell viability.
The FzM1 In Vivo efficacy was evaluated in an AGEs-RAGE activation model using male Wistar rats (6 weeks old). Administration of FzM1 (1 mg/kg/d; i.p.; once daily for 4 weeks) significantly reduced the production of Aβ1-40 and Aβ1-42 in the rat hippocampus. It inhibited the upregulation of Aβ metabolism-related proteins, including RAGE, BACE1, and APP, and downregulated pro-inflammatory cytokines such as p-NF-κB, TNF-α, and IL-1β. Additionally, FzM1 upregulated the antioxidant defense system by reducing ROS and LPO levels while increasing GSH content and the activities of SOD and GPx. These effects culminated in the alleviation of AGEs-induced memory impairment, evidenced by a significant decrease in escape latency in the Morris water maze test. For researchers seeking detailed FzM1 technical information, these results highlight its potential in treating neuroinflammation. In conclusion, FzM1 is a potent negative allosteric modulator of FZD4 that inhibits the WNT/β-catenin pathway and protects against AGEs-induced hippocampal damage.
Keywords
FzM1, 1680196-54-6, FzM 1, FzM-1, Wnt, β-catenin, Beta catenin, negative allosteric modulator, Frizzled receptor, FZD4, WNT5A-dependent WNT responsive element, WRE activity, WNT/β-catenin cascade, Inhibitor, inhibitor, inhibit
References
[1] Gennaro Riccio, et al. A Negative Allosteric Modulator of WNT Receptor Frizzled 4 Switches into an Allosteric Agonist. Biochemistry. 2018 Feb 6;57(5):839-851.
[2] Hong Y, et al. Effects of RAGE-Specific Inhibitor FPS-ZM1 on Amyloid-β Metabolism and AGEs-Induced Inflammation and Oxidative Stress in Rat Hippocampus. Neurochem Res. 2016 May;41(5):1192-9.
**Background**
Ovarian cancer is one of the most lethal gynecological malignancies, often characterized by late-stage diagnosis and a high rate of recurrence. High-grade serous ovarian carcinoma (HGSOC) represents a particularly aggressive subtype that requires the development of novel immunotherapeutic strategies. Recent research has highlighted the role of the Butyrophilin subfamily of the immunoglobulin superfamily, specifically BTN3A1 (CD277), in modulating the immune response. BTN3A1 is critical for the activation of Vγ9Vδ2 T cells, which are a potent subset of γδ T cells capable of exerting strong anti-tumor activity. By targeting this pathway, it is possible to redirect the immune system to recognize and eliminate malignant cells. In this context, we will introduce a fully human antibody designed for CTX-2026 Cancer research – CTX-2026.
**Definition**
CTX-2026 is a fully human IgG1 kappa antibody that specifically binds to CD277 (BTN3A1). According to the CTX-2026 description, this antibody is designed to enhance the cytotoxic activity of T cells against tumor cells expressing the target antigen.
**In Vitro and In Vivo Studies**
The efficacy of this antibody has been demonstrated through various experimental models. Regarding CTX-2026 in vitro activity, treatment with CTX-2026 (1 μg/mL; 12 h) successfully redirects the cytotoxic activity of Vγ9Vδ2 T cells from multiple donors against BTN3A1+ OVCAR3 cells or primary HGSOC cells. Furthermore, CTX-2026 (1 μg/mL; 6 d) has shown a rescuing effect on nonablated CD45+ T cells. These results are supported by CTX-2026 biological activity data, where flow cytometric analysis of K562 cells demonstrated successful binding and staining when using the antibody at a 1/200 dilution.
In terms of CTX-2026 In Vivo performance, the antibody was evaluated using NSG mice bearing NY-OVCAR3 tumors. Administration of CTX-2026 (5 mg/kg; i.p. every 3 days for 15 days) effectively delayed malignant progression in models derived from nine different donors, significantly inhibiting tumor growth. In conclusion, CTX-2026 is a fully human antibody that exhibits potent anti-tumor effects in ovarian tumor models by coordinating T cell responses.
Keywords
CTX-2026, CTX2026, CTX 2026, Others, zoledronate, human antibody, nivolumab, tumor, mice, NY-OVCAR3, ovarian tumor, Inhibitor, inhibitor, inhibit
References
**Background**
Chronic inflammation and uncontrolled cellular proliferation are hallmarks of various pathological conditions, including cancer and metabolic disorders. In particular, the invasion and metastasis of cancer cells are driven by the activity of matrix metalloproteinases (MMPs), which degrade the extracellular matrix to facilitate tumor spread. Additionally, the dysregulation of adipogenesis and lipid accumulation contributes significantly to the development of obesity and associated metabolic syndromes. Finding natural compounds that can modulate these pathways is of great research significance for developing novel therapeutic strategies. In this context, we will introduce a potent curcumin derivative – (E,E)-Bisdemethoxycurcumin.
**Definition**
(E,E)-Bisdemethoxycurcumin, also known as Curcumin III, is a polyphenol derivative of curcumin with established anti-inflammatory and anticancer activities.
**In Vitro and In Vivo Studies**
According to the (E,E)-Bisdemethoxycurcumin description, this compound exhibits significant biological effects across various cell models. In (E,E)-Bisdemethoxycurcumin in vitro studies, treatment with 1-10 μM for 5 hours significantly inhibited the invasion of HT1080 cancer cells without affecting their migration. Furthermore, treatment with 1-10 μM for 24 hours inhibited the secretion of MMP-9 in HT1080 cells, thereby affecting cancer cell invasion and metastasis. Specifically, concentrations of 5-50 μM for 24 hours significantly inhibited the activities of collagenase, MMP-2, and MMP-9 in HT1080 cells, although uPA activity remained unaffected. Regarding (E,E)-Bisdemethoxycurcumin Cancer research, the compound has been shown to induce apoptosis in activated hepatic stellate cells and attenuate gastric adenocarcinoma growth. Additionally, at 25 μM for 18-24 hours, it arrests the cell cycle at the G1 phase. In 3T3-L1 adipocytes, concentrations of 5-25 μM inhibit the expression of C/EBPα and PPARγ, reducing lipid accumulation by attenuating mitotic clonal expansion (MCE).
In (E,E)-Bisdemethoxycurcumin in vivo experiments, the compound was administered at 0.5% in the diet for 15 weeks to HFD-induced obese mice, which resulted in a significant reduction in both final body weight and body weight gain. In conclusion, (E,E)-Bisdemethoxycurcumin is a versatile polyphenol that inhibits cancer cell invasion and adipogenesis, making it a valuable tool for studying inflammation and obesity.
Keywords
(E,E)-Bisdemethoxycurcumin, 33171-05-0, (E,E)-Curcumin III, (E,E)-Didemethoxycurcumin, Apoptosis, Autophagy, adipogenesis, bisdemethoxycurcumin (BDMC), high-fat diet, mitotic clonal expansion (MCE), obesity, Inhibitor, inhibitor, inhibit
References
[1] Lee PJ, et al. Bisdemethoxycurcumin Induces Apoptosis in Activated Hepatic Stellate Cells via Cannabinoid Receptor 2. Molecules. 2015 Jan 14;20(1):1277-92.
[2] Chen J, et al. Natural borneol enhances bisdemethoxycurcumin-induced cell cycle arrest in the G2/M phase through up-regulation of intracellular ROS in HepG2 cells. Food Funct. 2014 Dec 24.
[3] Luo C, et al. Bisdemethoxycurcumin attenuates gastric adenocarcinoma growth by inducing mitochondrial dysfunction. Oncol Lett. 2015 Jan;9(1):270-274.
[4] Li YB, et al. Bisdemethoxycurcumin Increases Sirt1 to Antagonize t-BHP-Induced Premature Senescence in WI38 Fibroblast Cells. Evid Based Complement Alternat Med. 2013;2013:851714.
[5] Yodkeeree S, et al. Curcumin, demethoxycurcumin and bisdemethoxycurcumin differentially inhibit cancer cell invasion through the down-regulation of MMPs and uPA. J Nutr Biochem. 2009 Feb;20(2):87-95.
[6] Lai CS, et al. Bisdemethoxycurcumin Inhibits Adipogenesis in 3T3-L1 Preadipocytes and Suppresses Obesity in High-Fat Diet-Fed C57BL/6 Mice. J Agric Food Chem. 2016 Feb 3;64(4):821-30.